Neil Cataldi from Blueprint Capital discusses his investment thesis for Sanara Medtech (SMTI). Sanara is growing quickly, and Neil thinks continued growth in their product portfolio and hospitals they are approved to sell in will drive continued accelerated growth and long term compounding.Chapters0:00 Intro1:00 Sanara overview5:30 How is Sanara increasing their hospital reach?14:25 Discussing management21:10 Related party risks33:20 Breaking down SMTI's growth42:45 Sanara's telehealth ambitions1:01:10 Closing thoughts